



EFW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/683,815	
	Filing Date	October 9, 2003	
	First Named Inventor	Arnon ROSENTHAL	
	Art Unit	1614	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	38 + 254 Refs.	Attorney Docket Number	514712001500

ENCLOSURES (Check all that apply)		
☐ Fee Transmittal Form ☐ Fee Attached ☐ Amendment/Reply ☐ After Final ☐ Affidavits/declaration(s) ☐ Extension of Time Request ☐ Express Abandonment Request ☒ Information Disclosure Statement (3 pages) ☐ Certified Copy of Priority Document(s) ☐ Response to Missing Parts/Incomplete Application ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53	☐ Drawing(s) ☐ Licensing-related Papers ☐ Petition ☐ Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation Change of Correspondence Address ☐ Terminal Disclaimer ☐ Request for Refund ☐ CD, Number of CD(s) _____	☐ After Allowance communication to Technology Center (TC) ☐ Appeal Communication to Board of Appeals and Interferences ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) ☐ Proprietary Information ☐ Status Letter ☒ Other Enclosure(s) (please identify below): 1. Form PTO-1449 (17 pages in duplicate) 2. References (254) 3. Return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Jie Zhou - 52,395
Signature	
Date	August 20, 2004

CERTIFICATE OF HAND DELIVERY	
I hereby certify that this correspondence is being hand delivered to the Commissioner for Patents, U.S. Patent and Trademark Office, 220 20 th Street South, Customer Window, Mail Stop Amendment, Crystal Plaza Two, Lobby, Room 1B03, Arlington, Virginia 22202, on the date shown below.	
Date: August 30, 2004	Signature: (Shari Hall-White)



PATENT
Docket No. 514712001500

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand delivered to the Commissioner for Patents, U.S. Patent and Trademark Office, 220 20TH Street South, Customer Window, Mail Stop Amendment, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202 on the date shown below.

Dated:

August 30, 2004

Signature:

Shari Hall-White

Shari Hall-White

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Arnon ROSENTHAL et al.

Serial No.: 10/683,815

Filing Date: October 9, 2003

For: METHODS OF TREATING
ALZHEIMER'S DISEASE USING
ANTIBODIES DIRECTED AGAINST
AMYLOID BETA PEPTIDE AND
COMPOSITIONS THEREOF

Examiner: Not Yet Assigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
U.S. Patent and Trademark Office
220 20th Street South
Customer Window, Mail Stop Amendment
Crystal Plaza Two, Lobby,
Room 1B03
Arlington, VA 22202

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith.
The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 514712001500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 20, 2004

Respectfully submitted,

By: 
Jie Zhou
Registration No. 52,395

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5922
Facsimile: (650) 494-0792



Form PTO/SB-1449

Docket Number 514712001500

Application Number 10/683,815

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Amon ROSENTHAL et al.

Filing Date October 9, 2003

Group Art Unit 1614

Hand Delivered August 30, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/30/2001	2001/0018053	McMichael			
	2.	01/24/2002	2002/0009445	Du et al.			
	3.	02/14/2002	2002/0019335	Solomon et al.			
	4.	07/04/2002	2002/0086847	Chain			
	5.	07/18/2002	2002/0094335	Chalifour et al.			
	6.	08/01/2002	2002/0102261	Raso			
	7.	09/06/1983	4,403,112	Modaferri			
	8.	11/27/1984	4,485,045	Regen			
	9.	10/01/1985	4,544,545	Ryan et al.			
	10.	07/29/1986	4,603,112	Paoletti et al.			
	11.	05/19/1987	4,666,829	Glenner et al.			
	12.	06/30/1987	4,676,980	Segal et al.			
	13.	07/28/1987	4,683,195	Mullis et al.			
	14.	07/28/1987	4,683,202	Mullis			
	15.	06/14/1988	4,751,180	Cousens et al.			
	16.	06/28/1988	4,754,065	Levenson et al.			
	17.	09/06/1988	4,769,330	Paoletti et al.			
	18.	10/11/1988	4,777,127	Suni et al.			
	19.	11/01/1988	4,782,014	Serban et al.			
	20.	01/24/1989	4,800,159	Mullis et al.			
	21.	03/28/1989	4,816,567	Cabilly et al.			
	22.	01/02/1990	4,891,268	Fourez et al.			
	23.	06/19/1990	4,935,233	Bell et al.			
	24.	05/07/1991	5,013,556	Woodle et al.			
	25.	05/21/1991	5,017,487	Stunnenberg et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 514712001500

Application Number 10/683,815

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Amon ROSENTHAL et al.

Filing Date October 9, 2003

Group Art Unit 1614

Hand Delivered August 30, 2004

	26.	09/10/1991	5,047,335	Paulson et al.			
	27.	12/24/1991	5,075,109	Tice et al.			
	28.	11/17/1992	5,164,295	Kisilevsky et al.			
	29.	06/15/1993	5,219,740	Miller et al.			
	30.	07/27/1993	5,231,000	Majocha et al.			
	31.	08/10/1993	5,234,814	Card et al.			
	32.	11/16/1993	5,262,332	Selkoe			
	33.	12/14/1993	5,270,165	Van Nostrand et al.			
	34.	01/11/1994	5,278,299	Wong et al.			
	35.	01/31/1995	5,385,915	Buxbaum et al.			
	36.	06/06/1995	5,422,120	Kim			
	37.	08/15/1995	5,441,870	Seubert et al.			
	38.	03/19/1996	5,500,362	Robinson et al.			
	39.	04/23/1996	5,510,261	Goochee et al.			
	40.	06/11/1996	5,525,126	Basu et al.			
	41.	06/25/1996	5,530,101	Queen et al.			
	42.	08/13/1996	5,545,806	Longberg et al.			
	43.	08/13/1996	5,545,807	Surani et al.			
	44.	10/15/1996	5,565,332	Hoogenboom et al.			
	45.	10/29/1996	5,569,825	Lonberg et al.			
	46.	12/03/1996	5,580,717	Dower et al.			
	47.	12/03/1996	5,580,859	Felgner et al.			
	48.	12/17/1996	5,585,089	Queen et al.			
	49.	01/14/1997	5,593,846	Batt et al.			
	50.	02/18/1997	5,604,102	McConlogue et al.			
	51.	04/29/1997	5,625,126	Lonberg et al.			
	52.	05/27/1997	5,633,425	Lonberg et al.			
	53.	07/29/1997	5,652,092	Vitek et al.			
	54.	08/26/1997	5,661,016	Lonberg et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Amon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

	55.	10/21/1997	5,679,531	König et al.			
	56.	12/02/1997	5,693,478	König et al.			
	57.	12/02/1997	5,693,753	König et al.			
	58.	12/02/1997	5,693,761	Queen et al.			
	59.	12/02/1997	5,693,762	Queen et al.			
	60.	02/03/1998	5,714,471	Rowe et al.			
	61.	02/24/1998	5,721,130	Seubert et al.			
	62.	03/31/1998	5,733,743	Johnson et al.			
	63.	04/14/1998	5,739,277	Presta et al.			
	64.	05/12/1998	5,750,349	Suzuki et al.			
	65.	05/12/1998	5,750,373	Garrard et al.			
	66.	07/28/1998	5,786,180	König et al.			
	67.	09/15/1998	5,807,715	Morrison et al.			
	68.	09/29/1998	5,814,482	Dubensky, Jr. et al.			
	69.	10/13/1998	5,821,337	Carter et al.			
	70.	12/22/1998	5,851,996	Kline			
	71.	02/02/1999	5,866,692	Shitara et al.			
	72.	04/06/1999	5,891,991	Wasco et al.			
	73.	08/24/1999	5,942,400	Anderson et al.			
	74.	09/21/1999	5,955,317	Suzuki et al.			
	75.	09/28/1999	5,958,684	Van Leeuwen et al.			
	76.	11/02/1999	5,976,817	Davies-Heerena et al.			
	77.	12/07/1999	5,997,867	Waldmann et al.			
	78.	04/25/2000	6,054,297	Carter et al.			
	79.	06/06/2000	6,071,463	De'ath			
	80.	08/22/2000	6,107,029	Giordano			
	81.	08/22/2000	6,107,050	Alkon et al.			
	82.	09/05/2000	6,114,133	Seubert et al.			
	83.	11/07/2000	6,143,171	Van Aarsen			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Arnon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

	84.	01/30/2001	6,180,370	Queen et al.			
	85.	01/30/2001	6,180,377	Morgan et al.			
	86.	02/13/2001	6,187,756	Lee et al.			
	87.	04/03/2001	6,210,671	Co			
	88.	04/24/2001	6,221,645	Chrysler et al.			
	89.	04/24/2001	6,221,670	Cordell et al.			
	90.	07/03/2001	6,255,054	Hugon et al.			
	91.	07/24/2001	6,265,150	Terstappen et al.			
	92.	09/25/2001	6,294,171	McMichael			
	93.	09/25/2001	6,294,340	Strittmatter et al.			
	94.	12/18/2001	6,331,415	Cabilly et al.			
	95.	02/26/2002	6,350,861	Co et al.			
	96.	04/23/2002	6,376,471	Lawrence, III et al.			
	97.	07/12/2002	6,413,942	Felgner et al.			
	98.	08/20/2002	6,436,908	Koch et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	99.	12/06/1989	EP 0 345 242	Europe			Abstract	
	100.	10/10/1990	EP 0 391 714	Europe				
	101.	08/14/1991	EP 0 440 619	Europe				
	102.	12/23/1992	EP 0 519 596	Europe				
	103.	02/03/1993	EP 0 524 968	Europe				
	104.	08/31/1994	EP 0 613 007	Europe				
	105.	11/22/1995	EP 0 683 234	Europe				
	106.	12/05/2001	EP 1 160 256	Europe				
	107.	01/16/2002	EP 1 172 378	Europe				
	108.	08/10/1988	GB 2 200 651	Great Britain				
	109.	07/30/1987	WO 87/04462	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Amon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

	110.	03/09/1989	WO 89/01973	WIPO				
	111.	07/26/1990	WO 90/07936	WIPO				
	112.	10/04/1990	WO 90/11092	WIPO				
	113.	12/13/1990	WO 90/14841	WIPO				
	114.	01/10/1991	WO 91/00360	WIPO				
	115.	03/07/1991	WO 91/02805	WIPO				
	116.	04/04/1991	WO 91/04339	WIPO				
	117.	10/03/1991	WO 91/14445	WIPO				
	118.	12/12/1991	WO 91/18926	WIPO				
	119.	03/04/1993	WO 93/03769	WIPO				
	120.	04/01/1993	WO 93/06213	WIPO				
	121.	05/27/1993	WO 93/10218	WIPO				
	122.	06/10/1993	WO 93/11230	WIPO				
	123.	09/30/1993	WO 93/19191	WIPO				
	124.	09/30/1993	WO 93/19194	WIPO				
	125.	12/23/1993	WO 93/25234	WIPO				
	126.	12/23/1993	WO 93/25698	WIPO				
	127.	02/17/1994	WO 94/03622	WIPO				
	128.	03/03/1994	WO 94/04690	WIPO				
	129.	06/09/1994	WO 94/12649	WIPO				
	130.	10/27/1994	WO 94/23697	WIPO				
	131.	12/22/1994	WO 94/28938	WIPO				
	132.	01/05/1995	WO 95/00655	WIPO				
	133.	03/23/1995	WO 95/07994	WIPO				
	134.	05/04/1995	WO 95/11984	WIPO				
	135.	05/18/1995	WO 95/13084	WIPO				
	136.	05/26/1995	WO 95/13796	WIPO				
	137.	11/16/1995	WO 95/30763	WIPO				
	138.	06/06/1996	WO 96/17072	WIPO				

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>					Docket Number 514712001500		Application Number 10/683,815	
					Applicant Amnon ROSENTHAL et al.			
					Filing Date October 9, 2003		Group Art Unit 1614	
					Hand Delivered August 30, 2004			
	139.	08/22/1996	WO 96/25435	WIPO				
	140.	10/17/1996	WO 96/32105	WIPO				
	141.	12/19/1996	WO 96/40890	WIPO				
	142.	12/19/1996	WO 96/40896	WIPO				
	143.	11/13/1997	WO 97/42338	WIPO				
	144.	04/16/1998	WO 98/15179	WIPO				
	145.	06/11/1998	WO 98/24812	WIPO				
	146.	08/06/1998	WO 98/34120	WIPO				
	147.	09/11/1998	WO 98/39653	WIPO				
	148.	09/17/1998	WO 98/40484	WIPO				
	149.	10/15/1998	WO 98/44955	WIPO				
	150.	10/15/1998	WO 98/45444	WIPO				
	151.	10/22/1998	WO 98/46636	WIPO				
	152.	06/10/1999	WO 99/27944	WIPO				
	153.	11/18/1999	WO 99/58572	WIPO				
	154.	11/25/1999	WO 99/60024	WIPO				
	155.	11/23/2000	WO 00/69456	WIPO				
	156.	11/30/2000	WO 00/72280	WIPO			Abstract	
	157.	12/07/2000	WO 00/72876	WIPO				
	158.	03/15/2001	WO 01/18169	WIPO				
	159.	04/19/2001	WO 01/27160	WIPO				
	160.	06/07/2001	WO 01/39796	WIPO				
	161.	08/30/2001	WO 01/62801	WIPO				
	162.	10/18/2001	WO 01/ 77167	WIPO				
	163.	03/14/2002	WO 02/21141	WIPO				
	164.	05/16/2002	WO 02/38177	WIPO				
	165.	06/13/2002	WO 02/ 46237	WIPO				
	166.	09/12/2002	WO 02/070647	WIPO				
	167.	09/27/2002	WO 02/074240	WIPO				
EXAMINER:					DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.								

Form PTO-1449				Docket Number 514712001500		Application Number 10/683,815	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Amon ROSENTHAL et al.			
				Filing Date October 9, 2003		Group Art Unit 1614	
				Hand Delivered August 30, 2004			

	168.	11/07/2002	WO 02/088306	WIPO				
	169.	11/07/2002	WO 02/088307	WIPO				
	170.	12/05/2002	WO 02/096937	WIPO				

	Ref. No.	Title
	171.	Adelman, J.P. et al. (1983). " <i>In Vitro</i> Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," <i>DNA</i> 2(3):183-193.
	172.	Al-lazikami, B. et al. (1997). "Standard Conformations for the Canonical Structures of Immunoglobulins," <i>J. Molec. Biol.</i> 273:927-948.
	173.	Armour, K. L. et al. (1999). "Recombinant Human IgG Molecules Lacking Fcγ Receptor I binding and Monocyte Triggering Activities," <i>Eur. J. Immunol.</i> 29:2613-2624.
	174.	Bacsikai, B. J. et al. (2001). "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy," <i>Nature Medicine</i> 7(3):369-372.
	175.	Bacsikai, B. J. et al. (2002). "Non -Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β <i>In Vivo</i> by Immunotherapy," <i>J. Neurosci</i> 22(18):7873-7878.
	176.	Baekelandt, V. et al. (2000). "Gene Therapeutic Strategies for Neurodegenerative Diseases," <i>Current Opinion in Molecular Therapeutics</i> 2(5):540-554.
	177.	Balint, R. G. et al. (1993). "Antibody Engineering by Parsimonious Mutagenesis," <i>Gene</i> 137(1):109-118.
	178.	Bamberger, ME. Et al. (2001). "Microglial Interaction with Beta-Amyloid: Implications for the the Pathogenesis of Alzheimer's Disease," <i>Microscopy Research and Techniques</i> 54(2):59-70.
	179.	Barbas, III C. F. et al. (1994) "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," <i>Proc. Nat. Acad. Sci USA</i> 91:3809-3813.
	180.	Bard, F. (2000). "Peripherally Administered Antibodies Against Amyloid β - Peptide Enter the Central Nervous System and reduce Pathology in a Mouse Model of Alzheimer Disease," <i>Nature Medicine</i> 6(8): 916-919
	181.	Berkner, K. L. (1988). "Development of Adenovirus Vectors for the Expression of Heterologous Gene," <i>Biotechniques</i> 6:616-627.
	182.	Bird, R. E. et al. (1988). "Single-Chain Antigen-Binding Proteins," <i>Science</i> 242:423-426.
	183.	Blasko, I. et al. (2001). "Does IFN γ-Play A Role in Neurodegeneration," <i>Journal of Neuroimmunology</i> 116(1):1-4.
	184.	Boerner, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies from In Vitro-Primed Human Splenocytes," <i>J. Immunol.</i> 147(1):86-95.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.
--

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Amon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

185.	Boncristiano, S. et al. (2002). "Cholinergic Changes in the APP23 Transgenic Mouse Model of Cerebral Amyloidosis," <i>The Journal of Neuroscience</i> 22(8):3234-3243.
186.	Boyd, P. N. et al. (1996). "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," <i>Mol. Immunol.</i> 32(17/18):1311-1318.
187.	Brayden, D.J. et al. (2001). "Encapsulation in Biodegradable Microparticles Enhances Serum Antibody Response to Parentally-Delivered β -Amyloid in Mice," <i>Vaccine</i> 19(30):4185-4193.
188.	Brennan, M. et al. (1985). "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G ₁ Fragments," <i>Science</i> 229:81-83.
189.	Brown, B. A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.
190.	Calhoun, M. E. et al. (1999). "Neuronal Overexpression of Mutant Amyloid Precursor Protein Results in Prominent Deposition of Cerebrovascular," <i>Neurobiology</i> 6(24):14088-14093.
191.	Capel, P. J. A. et al. (1994). "Heterogeneity of Human IgG Fc Receptors," <i>Immunomethods</i> 4:25-34.
192.	Carter, D. B et al. (2001). "Human Apolipoprotein E4 Accelerates Beta-Amyloid Deposition in APPsw Transgenic Mouse Brain," <i>Annals of Neurology</i> 50(4):468-475.
193.	Carter, P. et al. (1992). "High Level Escherichia Coli Expression and Production of Bivalent Humanized Antibody Fragment," <i>Bio/Technology</i> 10:163-167.
194.	Chartier-Harlin, M.-C. et al. (2001). "Un Espoir Thérapeutique Dans La Maladie D'Alzheimer, Ou Peut-On Traiter Le Mal Par Le Mal," <i>M/S Nouvelles Medicine Sciences</i> 17(4):523-524 (Original version).
195.	Chauhan, N. B. et al. (2001). "Distribution of Intraventricularly Administered Anti-amyloid-Beta Peptide (A β) Antibody in the Mouse Brain," <i>Journal of Neuroscience Research</i> 66:231-235.
196.	Cherny, R.A et al (2001). "Treatment with A Copper-Zinc Chelator Markedly and Rapidly Inhibits Beta-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice," <i>Neuron</i> 30(3):665-676.
197.	Chiou, H. C. et al. (1994). "In Vivo Gene Therapy via Receptor-Mediated DNA Delivery," <i>In Gene Therapeutics: Methods and Applications of Direct Gene Transfer</i> , Wolff, J. A., ed., Birkhauser, pp. 143-156.
198.	Chishti, M.A. et al. (2001). "Early-Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein," <i>Journal of Biological Chemistry</i> 276(24):21562-21570.
199.	Chothia, C. et al. (1989). "Conformations of Immunoglobulin Hypervariable Regions 395," <i>Nature</i> 342:877-883.
200.	Chung, H.Y. et al. (2001). "Uptake of Fibrillar β -Amyloid by Microglia Isolated from MSR-A (Type I and Type II) Knockout Mice," <i>NeuroReport</i> 12(6):1151-1154.
201.	Clackson, T. et al. (1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628.
202.	Clynes, R. et al. (1998). "Fc Receptors Are Required in Passive and Active Immunity to Melanoma,"

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449		Docket Number 514712001500	Application Number 10/683,815
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Arnon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
		PNAS USA 95:652-656.	
	203.	Cohen, J. (1993). "Naked DNA Points Way to Vaccines," <i>Science</i> 259:1691-1692.	
	204.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld, R. A. et al., Alan R.Liss, Inc., pp. 77-96.	
	205.	Connelly, S. et al. (1995). "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," <i>Human Gene Therapy</i> 6:185-193.	
	206.	Cunningham, B. C. et al. (1989). "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> 244:1081-1085.	
	207.	Curiel, D. T. (1992). "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," <i>Hum. Gene Ther</i> 3:147-154.	
	208.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.	
	209.	Dayhoff, M.O. et al. (1978). "A Model of Evolutionary Change in Proteins," Chapter 22 <i>In Atlas of Protein Sequence and Structure</i> , National Biomedical Research Foundation, Washington DC Volume 5, Supplemental 3 pp. 345-352.	
	210.	De Strooper, B. et al. (2001). "Alzheimer's Disease: An Inflammatory Drug Prospect," <i>Nature</i> 414:159-160.	
	211.	DeHaas, M. et al. (1995). "FC γ Receptors of Phagocytes," <i>J. Lab. Clin. Med.</i> 126(4):330-341.	
	212.	DeMattos, R. B. (2001). "Peripheral Anti-A β Antibody Alters CNS and Plasma A β Burden in a Mouse Model of Alzheimer's Disease," <i>PNAS</i> 98(15):8850-8855.	
	213.	DeMattos, R. B. et al. (2002). "Brain to Plasma Amyloid- β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease," <i>Science</i> 295:2264-2267.	
	214.	Dodart, J.-C. et al. (2002). "Immunization Reverses Memory Deficits Without Reducing Brain A β Burden in Alzheimer's Disease Model," <i>Nat. Neuroscience</i> 5(5):452-457.	
	215.	Duff, K. (1999). "Curing Amyloidosis: Will it Works in Humans," <i>Trends in Neurosciences</i> 22(11):485-486.	
	216.	Duff, K. et al. (2001). "Progress in the Modeling of Neurodegenerative Diseases in Transgenic Mice," <i>Current Opinion in Neurology</i> 14(4):441-447.	
	217.	El-Agnaf, O.M.A et al. (2001). "Non-Fibrillar Oligomeric Species of the Amyloid ABri Peptide, Implicated in Familial British Dementia, Are More Potent at Inducing Apoptotic Cell Death than Protofibrils or Mature Fibrils," <i>Journal of Molecular Biology</i> 310(1):157-168.	
	218.	Eppstein, D. A. et al. (1985). "Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by A Cell Membrane Receptor," <i>PNAS USA</i> 82:3688-3692.	
	219.	Esiri, M. (2001). "Is an Effective Immune Intervention for Alzheimer's Disease in Prospect?" <i>Trends In Pharmacological Sciences</i> 22(1):2-3.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Amon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

220.	Fassbender, K. (2001). "Alzheimer's Disease: Molecular Concepts and Therapeutic Targets," <i>Naturwissenschaften</i> 88:261-267.
221.	Findeis, M. A. et al. (1993). "Targeted Delivery of DNA for Gene Therapy via Receptors," <i>TibTech</i> 11:202-205.
222.	Fisher-Hoch, S. P. et al. (1989). "Protection of Rhesus Monkeys from Fatal Lassa Fever by Vaccination with A Recombinant Vaccinia Virus Containing the Lassa Virus Glycoprotein Gene," <i>PNAS USA</i> 86:317-321.
223.	Fishman, C.E. et al. (2001). "Statistical Aspects of Quantitative Image Analysis of β -Amyloid in the APP ^{V717F} Transgenic Mouse Model Alzheimer's Disease," <i>Journal of Neuroscience Methods</i> 108(2):145-152.
224.	Flexner, C. et al (1990). "Attenuation and Immunogenicity in Primates of Vaccinia Virus Recombinants Expressing Human Interleukin-2," <i>Vaccine</i> 8:17-21.
225.	Frenkel, D. et al. (2000). "Immunization Against Alzheimers' β -Amyloid Plaques via EFRH Phage Administration," <i>PNAS</i> 97(21):11455-11459.
226.	Fukuta, T. (2001). "Difference in Toxicity of β -Amyloid Peptide with Aging in Relation to Nerve Growth Factor Content in Rat Brain," <i>Journal of Neural Transmission</i> 108(2):221-230.
227.	Galasko, D. (2001). "New Approaches to Diagnose and Treat Alzheimer's Disease - A Glimpse of the Future," <i>Clinic in Geriatric Medicine</i> 17(2):393-410.
228.	Garcia, P. et al. (1986). "Nucleotide Sequence and Expression of the Pneumococcal Autolysin Gene from Its Own Promoter In <i>Escherichia Coli</i> ," <i>Gene</i> 43:265-272.
229.	Gazzano-Santoro, H. et al. (1997). "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody," <i>J. Immunol. Methods</i> 202:163-171.
230.	Geerligs, H. et al. (1989). "The Influence of Different Adjuvants on the Immune Response to a Synthetic Peptide Comprising Amino Acid Residues 9-21 of Herpes simplex Virus Type 1 Glycoprotein D," <i>J. Immunol. Methods</i> 124(1):95-102.
231.	Griffith, A. D. et al. (1993). "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries," <i>EMBO J.</i> 12(2):725-734.
232.	Guyer, R. L. et al. (1976). "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors," <i>J. Immunol.</i> 117(2):587-593.
233.	Guzman, R. J. et al. (1993). "Efficient and Selective Adenovirus-Mediated Gene Transfer Into Vascular Neointima," <i>Circulation</i> 88(6):2838-2848.
234.	Guzman, R. J. et al. (1993). "Efficient Gene Transfer Into Myocardium by Direct Injection of Adenovirus Vectors," <i>Cir. Res.</i> 73:1202-1207.
235.	Haass, C. (2002). "New Hope for Alzheimer Disease Vaccine," <i>Nature Medicine</i> 8(11):1195-1196.
236.	Hadland, B.K. et al. (2001). " γ -Secretase Inhibitors Repress Thymocyte Development," <i>PNAS USA</i> 98(13):7487-7491.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712001500	Application Number 10/683,815
		Applicant Amon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
	237.	Hardy, J. (1996). "New Insights Into the Genetics of Alzheimer's Disease," <i>Ann. Med.</i> 28:255-258.	
	238.	Hardy, J. (1997). "Amyloid, the Presenilins and Alzheimer's Disease," <i>Trends Neurosci.</i> 20(4):154-159.	
	239.	Hawkins, R. E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation," <i>J. Mol. Biol.</i> 226:889-896.	
	240.	Hein, J. (1990). "Unified Approach to Alignment and Phylogenies" Chapter 39 <i>In Methods of Enzymology</i> , Academic Press, Inc., Volume 183 pp. 626-645	
	241.	Higgins, D. G et al. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," <i>CABIOS Communications</i> 5(2):151-153.	
	242.	Hock, C. et al. (2002). "Generation of Antibodies Specific for β -Amyloid by Vaccination of Patients with Alzheimer Disease," <i>Nature Medicine</i> 8(11):1270-1275.	
	243.	Holcomb, L. A. et al. (1999). "Behavioral Changes in Transgenic Mice Expressing both amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits," <i>Behav. Gen.</i> 29(3):177-185.	
	244.	Holcomb, L.A et al. (1998). "Accelerated Alzheimer-Type Phenotype in Transgenic Mice Carrying bot Mutant <i>Amyloid Precursor Protein</i> and <i>Presenilin 1</i> Transgenes," <i>Nat. Med.</i> 4:97-100.	
	245.	Holliger, P. et al. (1993). "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," <i>PNAS</i> 90:6444-6448.	
	246.	Hoogenboom, H. R. et al. (1991). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro," <i>J. Mol. Biol.</i> 227:381-388.	
	247.	Hoozemans, J.J.M. et al. (2001). "Immunological Aspects of Alzheimer's Disease- Therapeutic Implication," <i>BioDrugs</i> 15(5):325-337.	
	248.	Hsiao, K. et al. (1996). "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> 274:99-102	
	249.	Hsu, T.-A. et al. (1997). "Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in <i>Triphophusia ni</i> Cells," <i>J. Biol. Chem.</i> 272(14):9062-9070.	
	250.	Huse, J. T et al. (2000). "Closing in on the Amyloid Cascade Recent Insights Into the Cell Biology of Alzheimer's Disease," <i>Molecular Neurobiology</i> 22(1-3):81-98.	
	251.	Hwang, K. J. et al. (1980). "Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study," <i>Proc. Natl Acad. Sci USA</i> 77(7):4030-4034.	
	252.	Illiades, P. et al. (1997). "Triabodies: Single Chain Fv Fragments Without a Linker Form Trivalent Trimers," <i>FEBS Letters</i> 409:437-441.	
	253.	Irizarry, M. C. et al. (2001). "Alzheimer Disease Therapeutics," <i>Journal of Neuropathology and Experimental Neurology</i> 60(10):923-928.	
	254.	Jackson, J. R. et al. (1995). "In Vitro Antibody Maturation," <i>J. Immunol.</i> 154(7):3310-3319.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712001500	Application Number 10/683,815
		Applicant Arnon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
	255.	Janus, C. et al. (2000). "A β Peptide Immunization Reduces Behavioural Impairment and Plaques in a Model of Alzheimer's Disease," <i>Nature</i> 408:979-982.	
	256.	Janus, C. et al. (2001). "Transgenic Mouse Models of Alzheimer's Disease," <i>Physiology & Behavior</i> 73(5):873-886.	
	257.	Jefferis R. et al. (1997). "Glycosylation of Antiody Molecules: Structural and Functional Significance," <i>Chem. Immunol.</i> 65:111-128.	
	258.	Jhee, S. et al. (2001). " β -Amyloid Therapies in Alzheimer's Disease," <i>Expert Opinion on Investigational Drugs</i> 10(4):593-605.	
	259.	Johnson, K. S. et al. (1993). "Human Antibody Engineering," <i>Current Opinion in Structural Biology</i> 3:564-571.	
	260.	Jolly, D. (1994). "Viral Vector Systems for Gene Therapy," <i>Cancer Gene Therapy</i> 1(1):51-64.	
	261.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.	
	262.	Kabat, E. A. et al. (1991). "Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens, β_2 -Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, C-Reactive Protein, Thymopoietin, Integrins, Post-gamma Globulin, α_2 -Macroglobulins, and Other Related Proteins," <i>In Sequences of Proteins of Immunological Interest</i> , US Dept. of Health and Human Services NIH Publication NO. 91-3242. , Fifth edition(Table of Contents only).	
	263.	Kakimura, J. (2001). "BiP/GRP78-Induced Production of Cytokines and Uptake of Amyloid- β (1-42 Peptide in Microglia," <i>Biochemical and Biophysical Research Communications</i> 281(1):6-10.	
	264.	Kaplitt, M. G. et al. (1994). "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," <i>Nature Genetics</i> 8:148-153.	
	265.	Karlsson, R. et al. (1994). "Kinetic and Concentration Analysis Using BIA Technology," <i>Methods: A Companion to Methods in Enzymology</i> 6:99-110.	
	266.	Kenney, J. S. et al. (1989). "Influence of Adjuvants on the Quantity, Affinity, Isotype and Epitope Specificity of Murine Antibodies," <i>J. Immunol. Methods</i> 121(1):157-166.	
	267.	Kim, J-K. et al. (1994). "Localization of the Site of the Murine IgG1 Molecule that is Involved in Binding to the Murine Intestinal Fc Receptor," <i>J. Immunol.</i> 24:2429-2434.	
	268.	Kimura, O. et al. (1994). "Retroviral Delivery of DNA Into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," <i>Human Gene Therapy</i> 5(7):845-852.	
	269.	Klein, W.L. et al. (2001). "Targeting Small A Beta Oligomers: the Solution to an Alzheimers' Disease Conundrum," <i>Trends in Neurosciences</i> 24(4):219-224.	
	270.	Kohler, G. et al. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.	
	271.	Kolls, J. et al. (1994). "Prolonged and Effective Blockade of Tumor Necrosis Factor Activity Though	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712001500	Application Number 10/683,815
		Applicant Arnon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
		Adenovirus-Mediated Gene Transfer," <i>PNAS USA</i> 91:215-219.	
	272.	Kortt, A. A. et al. (1997). "Single-Chain Fv Fragments of Anti-Neuraminidase Antibody NC10 Containing Five- and Ten-Residue Linkers Form Dimers and With Zero-Residue Linker a Trimer," <i>Protein Engineering</i> 10(4):423-433.	
	273.	Kotilinek, L.A et al. (2002). "Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease," <i>J. Neurosci</i> 22(15):6331-6335.	
	274.	Kril, J. J. (2001). "Alzheimer's Disease: It's Diagnosis and Pathogenesis," <i>In International Review of Neurobiology</i> , Bradley, R. J. et al., eds., Academic Press, Inc., Volume 48 pp. 167-217.	
	275.	Lee, VMY (2001). "A Beta Immunization: Moving A Beta Peptide from Brain to Blood," <i>PNAS</i> 98(16):8931-8932.	
	276.	Lin, Y. M. (2001). "Amyloid Fibril Formation in Microwell Plates for Screening of Inhibitors," <i>Amyloid-Journal of Protein Folding Disorders</i> 8(3):183-193.	
	277.	Lobuglio, A. F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>PNAS USA</i> 86:4420-4224.	
	278.	Maimone, D. et al. (2001). "Pharmacogenomics of Neurdegenerative Diseases," <i>European Journal of Phamacology</i> 413(1):11-29.	
	279.	Maratea, D. et al. (1985). "Deletion and Fusion Analysis of the Phage ΦX174 Lysis Gene E," <i>Gene</i> 40:39-46.	
	280.	Mark, J. D. et al. (1991). "By-Passing Immunization Human Antibodies from V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.	
	281.	Marks, et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10:779-783.	
	282.	Martin, F. J. et al. (1982). "Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles," <i>J. Biol. Chem.</i> 257(1):286-288.	
	283.	McCafferty, J. et al. (1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348:552-554.	
	284.	McGowan, E. (1999). "Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes," <i>Neurobiology of Disease</i> 6:231-244.	
	285.	McLaurin, J. et al. (2002). "Therapeutically Effective Antibodies Against Amyloid-β Peptide Target Amyloid-β Residues 4-10 and Inhibit Cytotoxicity and Fibrillogenesis," <i>Nature Medicine</i> 8(11):1263-1269.	
	286.	Merrifield, R. B. (1963). "Solid Phase Peptide Synthesis: I. the Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2146.	
	287.	Milstein, C. et al. (1983). "Hybrid Hybridomas and Their Use Immunohistochemistry," <i>Nature</i> 305:537-539.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712001500	Application Number 10/683,815
		Applicant Arnon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
	288.	Mitrasinovic, O.M. et al. (2001). "Overexpression of Macrophage Colony-Stimulating Factor Receptor on Microglial Cells Induces an Inflammatory Response," <i>Journal of Biological Chemistry</i> 276(32):30142-30149.	
	289.	Mohajeri, M. H. et al. (2002). "Passive Immunization Against β -Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer's Disease Mutation," <i>The Journal of Biological Chemistry</i> 277(36):33012-33017.	
	290.	Morgan, D et al. (2000). "A β Peptide Vaccination Prevents Memory Loss in an Animal Model of Alzheimer's Disease," <i>Nature</i> 408:982-985.	
	291.	Morimoto, K. et al. (1992). "Single-Step Purification of F(ab') ₂ Fragments of Mouse Monoclonal Antibodies (Immunoglobins G1) by Hydrophobic Interaction High Performance Liquid Chromatography Using TSKgel Phenyl-5PW," <i>In Journal of Biochemical and Biophysical Methods</i> , Chignell, C.F. et al., eds., Elsevier Science Publishers, B.V. Volume 24 pp. 107-117.	
	292.	Moss, B. et al. (1989). "Vaccinia Virus Expression Vectors," <i>Annals of the New York Academy of Sciences: Biomedical Science and the Third World</i> 569:86-103.	
	293.	Mullis, K.B. et al., eds. (1994). <i>The Polymerase Chain Reaction</i> , Birkäuser Press, pp. xv-xvii. (Table of Contents Only)	
	294.	Murphy, C.L. et al. (2001). "Chemical Typing of Amyloid Protein Contained in Formalin-Fixed Paraffin-Embedded Biopsy Specimens," <i>American Journal of Clinical Pathology</i> 116(1):135-142.	
	295.	Murphy, J. R. et al (1986). "Genetic Construction, Expression, and Melanoma-Selective Cytotoxicity of a Diphtheria Toxin-Related α -Melanocyte-Stimulating Hormone Fusion Protein," <i>PNAS USA</i> 83:8258-8262.	
	296.	Myers, E.W. et al. (1988). "Optimal Alignments Linear Space," <i>CABIOS</i> 4(1):11-17.	
	297.	Nunan, J. et al. (2001). "The C-Terminal Fragment of the Alzheimer's Disease Amyloid Protein Precursor is Degraded by Proteasome-Dependent Mechanism Distinct from Gamma-Secretase," <i>European Journal of Biochemistry</i> 268(20):5329-5336.	
	298.	Orttega, S. et al. (1992). "Single-Step Purification on Deae-Sephacel of Recombinant Polypeptides Produced in <i>Escherichia Coli</i> ," <i>Biotechnology</i> 10:795-798.	
	299.	Pfeifer, M. et al. (2002). "Cerebral Hemorrhage After Passive Anti-A β Immunotherapy," <i>Science</i> 298:1379.	
	300.	Philip, R. et al. (1994). "Efficient and Sustained Gene Expression in Primary T. Lymphocytes and Primary and Cultured Tumor," <i>Mol. Cell. Biol.</i> 14:2411-2418.	
	301.	Poljak, R. et al. (1994). "Production and Structure of Diabodies," <i>Structure</i> 2:1121-1123.	
	302.	Quadt, R. et al. (1993). "Characterization of a Host Protein Associated with Brome Mosaic Virus RNA-Dependent RNA Polymerase," <i>PNAS USA</i> 90:1498-1502.	
	303.	Ravetch, J. V. et al. (1991). "Fc Receptors," <i>In Annual Review of Immunology</i> , Paul, W. E. et al. , eds., Annual Reviews, Inc. Palo Alto, California, Volume 9 pp. 457-492. (Includes Table of Contents).	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 514712001500	Application Number 10/683,815
		Applicant Arnon ROSENTHAL et al.	
		Filing Date October 9, 2003	Group Art Unit 1614
		Hand Delivered August 30, 2004	
	304.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.	
	305.	Robinson, E. D. (1971). "Comparison of Labeled Trees with Valency Three," <i>Comb. Theor.</i> 11:105-119.	
	306.	Rolland, A. P. (1998). "From Genes to Gene Medicines: Recent Advances in Nonviral Gene Delivery," <i>Crit. Rev. Therap Drug Systems</i> 15(2):143-198.	
	307.	Rosenfeld, M. A. et al. (1991). "Adenovirus-Mediated Transfer of a Recombinant α -Antitypsin Gene to the Lung Epithelium in Vivo," <i>Science</i> 252(5004):431-434.	
	308.	Saitou, N. et al. (1987). "The Neighbor-Joining Method: A New Method for Reconstructing Phylogenetic Tree," <i>Mol. Biol. Evol.</i> 4:406-425.	
	309.	Schier, R. et al. (1995). "Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis," <i>Gene</i> 169:147-155.	
	310.	Schwartz, R. M. et al. (1978). "Matrices for Detecting Distant Relationships," Chapter 23 <i>In Atlas of Protein Sequence and Structure</i> , Library of Congress Card Catalogue Number 65-29342, ISBN 0-912466-07-03, National Biomedical Research Foundation: Maryland, Volume 5, Supplement 3 pp. 353-358.	
	311.	Selkoe, D. J. (2001). "Presenilin Notch, and the Genesis and Treatment of Alzheimer's Disease," <i>PNAS USA</i> 98(20):11039-11041.	
	312.	Severino, K. A. et al. (1988). "Biosynthesis of Thyrotropinreleasing Hormone by a Rat Medullary Thyroid Carcinoma Cell Line," <i>J. Biol. Chem.</i> 263:620-623.	
	313.	Shaw, D. R. et al. (1987). "Characterization of a Mouse/Human Chimirc Monoclonal Antibody (17-A) to a Colon Cancer Turmor-Associated Antigen," <i>J. Immunology</i> 138:4534-4538.	
	314.	Sheets, M. D. et al. (1998). "Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens," <i>PNAS USA</i> 95:6157-6162.	
	315.	Shenk, D. (2002). "Amyloid- β Immunotherapy for Alzheimer's Disease: the End of the Beginning," <i>Nature</i> 3:824-828.	
	316.	Shenk, D. et al. (1999). "Immunization with Amyloid- β Attenuates Alzheimer Disease-Like Pathology in the PDAPP Mouse," <i>Nature</i> 400:173-177.	
	317.	Shenk, D.B et al. (2000). " β -Peptide Immunization - A Possible New Treatment for Alzheimer Disease," <i>Archives of Neurology</i> 57(7):934-936.	
	318.	Smith, T. W. et al. (1977). "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication," <i>In Antibodies in Human Diagnosis and Therapy</i> , Haber et al., eds, Raven Press, New York, pp. 365-389.	
	319.	Sneath, P. H. A. et al., eds. (1973). <u>Numerical Taxonomy the Principles and Practice of Numerical Classification</u> , Freeman Press, San Francisco, pp. vi-ix,	
	320.	Solomon, B. et al (1996). "Monoclonal Antibodies Inhibit in vitro Fibrillar Aggregation of the	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 514712001500	Application Number 10/683,815
	Applicant Amon ROSENTHAL et al.	
	Filing Date October 9, 2003	Group Art Unit 1614
	Hand Delivered August 30, 2004	

	Alzheimer β -Amyloid Peptide," <i>Proc. National Acad. Sci</i> 93:452-455.
321.	Solomon, B. et al. (1997). "Disaggregation of Alzheimer β -amyloid by Site-Directed mAb," <i>PNAS</i> 94:4109-4112.
322.	Stalder, M. et al. (2001). "3D-Reconstruction of Microglia and Amyloid in APP23 Transgenic Mice: No Evidence of Intracellular Amyloid," <i>Neurobiology of Aging</i> 22(3):427-434.
323.	Steiner, H. et al. (2000). "Intramembrane Proteolysis by Presenillins," <i>Nature Reviews Molecular Cell Biology</i> 1(3):217-224.
324.	Stoute, J. A et al. (1997). "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria," <i>New Engl. J. Med.</i> 336(2):86-91.
325.	Sturchler-Pierrat, C. et al. (1997). "Two Amyloid Precursor Protein Transgenic Mouse Models with Alzheimer Disease-Like Pathology," <i>PNAS USA</i> 94:13287-13292.
326.	Suresh, M. R. et al. (1986). "Bispecific Monoclonal Antibodies from Hybrid Hybridomas," Chapter 17 <i>In Methods in Enzymology</i> Volume 121 pp. 211-229.
327.	Tanzi, R. E. et al. (1996). "The Gene Defects Responsible for Familial Suzanne Y. Guenette, and Wilma Wasco," <i>Neurobiol. Dis.</i> 3:159-168.
328.	Town, T. et al. (2001). "Characterization of Murine Immunoglobulin G Antibodies Against Human Amyloid- β 1-42," <i>Neuroscience Letters</i> 307:101-104.
329.	Turner, R. S. (2001). "Alzheimer's Disease in Man and Transgenic Mice – Females at Higher Risk," Article no. 0016 <i>American Journal of Pathology</i> 158(3):797-801.
330.	Ulmer, J. B. et al. (1993). "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," <i>Science</i> 259:1745-1749.
331.	Umana, P. et al. (1999). "Engineered Glycoforms of an Antiuroblastoma IgG1 with Optimized Antibody-Dependent Cellular Cytotoxic Activity," <i>Nature Biotech</i> 17:176-180.
332.	Vaughan, T. J. et al. (1996). "Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-Immunized Phage Display Library," <i>Nature Biotechnology</i> 14:309-314.
333.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting and Antilysozyme Activity," <i>Science</i> 239:1534-1536.
334.	Walker, L.C et al. (2000). "The Cerebral Proteopathies – Neurodegenerative disorders of Protein Conformation and Assembly," <i>Molecular Neurobiology</i> 21(1-2):83-95.
335.	Waterhouse, P. et al. (1993). "Combinatorial Infection and In-Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," <i>Nucl. Acids Res.</i> 21:2265-2266.
336.	Weggen, S. et al. (2001). "A Subset of NSAIDs Lower Amyloidogenic A β 42 Independently of Cyclooxygenase Activity," <i>Nature</i> 414:212-216.
337.	Weninger, S.C. et al. (2001). "Inflammation and Alzheimer Disease: the Good, The Bad, and The Ugly," <i>Nature Medicine</i> 7(5):527-528.
338.	Wilbur, W. J. et al. (1983). "Rapid Similarity Searches of Nucleic Acid and Protein Data Banks," <i>PNAS USA</i> 80:726-730.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

Docket Number 514712001500

Application Number 10/683,815

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Amon ROSENTHAL et al.

Filing Date October 9, 2003

Group Art Unit 1614

Hand Delivered August 30, 2004

- | | |
|------|---|
| 339. | Wilcock, D. M. et al. (2001). "Number of A β Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels," <i>DNA and Cell Biology</i> 20(11):731-736. |
| 340. | Winkler, DT et al. (2001). "Spontaneous Hemorrhagic Stroke in a Mouse Model Cerebral Amyloid Angiopathy," <i>Journal of Neuroscience</i> 21(5):1619-1627. |
| 341. | Winter, G. et al. (1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299. |
| 342. | Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455. |
| 343. | Wittwer, A. J. et al. (1990). "Glycosylation at ASn-184 Inhibits the Conversation of Single-Chain to Two-Chain Tissue-Type Plasminogen Activator by Plasmin," <i>Biochem</i> 29:4175-4180. |
| 344. | Woffendin, C. et al. (1994). "NonViral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene Into Primary Human T Cells," <i>PNAS USA</i> 91:11581-11585. |
| 345. | Wright, A. and Morrison, S. L. (1997). "Effect of Glycosylation on Antibody Function: Implacations for Genetic Engineering," <i>TibTech</i> 15:26-32. |
| 346. | Wu, C. H. (1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements in Vivo," <i>J. Biol. Chem.</i> 264:16985-16987. |
| 347. | Wu, G. Y. et al. (1991). "Receptor-Mediated Gene Delivery in Vivo," <i>The Journal of Biological Chemistry</i> 266(22):14338-14342 |
| 348. | Wu, G. Y. et al. (1994). "Incorporation of Adenovirus Into a Ligand -Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," <i>J. Biol. Chem</i> 269:11542-11546. |
| 349. | Wyss, D. F. et al. (1996). "The Structural Role of Sugars in Glycoproteins," <i>Current Opinion Biotech.</i> 7:409-416. |
| 350. | Yelton, D. E. et al. (1995). "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," <i>J. Immunol.</i> 155:1994-2004. |
| 351. | Zenke, M. et al. (1990). "Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hemapopoietic Cells," <i>PNAS USA</i> 87:3655-3659. |
| 352. | Zola, H. (1987). "Using Monoclonal Antibodies: Soluble Antigens," Chapter 6 <i>In Monoclonal Antibodies: A Manual of Techniques</i> , CRC Press, Inc. pp. 147-158. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.